-+ 0.00%
-+ 0.00%
-+ 0.00%

BIO-THERA SOLUTIONS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY FOR BAT8013, AN ANTIBODY DRUG CONJUGATE TARGETING CD25 FOR THE TREATMENT OF ADVANCED SOLID TUMORS

Reuters·07/23/2026 12:48:11

Please log in to view news